1. First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma.
- Author
-
Gibouin VC, Durand M, Boudesco C, Hermetet F, Nozickova K, Chassagne-Clement C, Abdelwahed M, Klener P, Garrido C, and Jego G
- Subjects
- Humans, Phosphorylation drug effects, Animals, Mice, Pyrimidines pharmacology, Cell Line, Tumor, Tumor Cells, Cultured, Mice, SCID, Quinazolines, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse metabolism, Lymphoma, Large B-Cell, Diffuse pathology, Syk Kinase antagonists & inhibitors, Syk Kinase metabolism, Receptors, Antigen, B-Cell metabolism, Signal Transduction drug effects, HSP110 Heat-Shock Proteins metabolism, Xenograft Model Antitumor Assays
- Abstract
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is driven by aberrant activation of the B-cell receptor (BCR) and the TLR/MyD88 signaling pathways. The heat-shock protein HSP110 is a candidate for their regulation as it stabilizes MyD88. However, its role in overall BCR signaling remains unknown. Here, we used first-in-class HSP110 inhibitors to address this question. HSP110 inhibitors decreased the survival of several ABC-DLBCL cell lines in vitro and in vivo, and reduced the phosphorylation of BCR signaling kinases, including BTK and SYK. We identified an interaction between HSP110 and SYK and demonstrated that HSP110 promotes SYK phosphorylation. Finally, the combination of the HSP110 inhibitor with the PI3K inhibitor copanlisib decreases SYK/BTK and AKT phosphorylation synergistically, leading to suppression of tumor growth in cell line xenografts and strong reduction in patient-derived xenografts. In conclusion, by regulating the BCR/TLR signaling pathway, HSP110 inhibitors are potential drug candidates for ABC-DLBCL patients., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF